Basilea News Basilea News en Sat, 25 Jun 2016 14:18:19 +0200 Sat, 25 Jun 2016 14:18:19 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting]]>
  • Clinical data reported from completed phase 1/2a study of BAL101553, with once-weekly 2-hour infusion showing signals of clinical activity
  • Design of ongoing phase 1/2a study with once-daily oral BAL101553 presented, with four dose cohorts completed
  • Design of ongoing BAL3833 oral phase 1 study presented, with four dose cohorts completed
  • ]]>
    Thu, 09 Jun 2016 07:15:00 +0200
    <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> Thu, 21 Apr 2016 18:30:10 +0200 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]>
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200
    <![CDATA[Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program]]> Wed, 20 Apr 2016 07:15:00 +0200 <![CDATA[Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)]]>
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
  • ]]>
    Fri, 15 Apr 2016 07:15:00 +0200
    <![CDATA[Basilea issues agenda for Annual General Meeting of Shareholders]]>
  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board
  • ]]>
    Tue, 15 Mar 2016 07:15:00 +0100
    <![CDATA[Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis]]> Wed, 09 Mar 2016 07:15:00 +0100 <![CDATA[Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany]]> Fri, 04 Mar 2016 07:15:00 +0100 <![CDATA[Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom]]> Basel, Switzerland, March 03, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in the UK. The symposium will be held on March 3, 2016 as part of the 7th Advances Against Aspergillosis conference in Manchester, UK. It will be chaired by Prof. David W. Denning, Professor of Infectious Diseases, National Aspergillosis Centre, University of Manchester and will focus on current challenges and recent developments in the management of invasive mold infections.

    Thu, 03 Mar 2016 07:15:00 +0100
    <![CDATA[Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe]]>
  • CRESEMBA® approval in U.S. and Europe and launched in the U.S. by Astellas
  • Zevtera® launched in major European countries
  • Tumor checkpoint controller BAL101553 interim phase 2a (i.v.) study data reported and phase 1 (oral) study initiated; oncology panRAF-SRC kinase inhibitor BAL3833 phase 1 initiated
  • CHF 200 million convertible bonds issued, year-end cash and short-term investments of CHF 364.7 million
  • ]]>
    Mon, 29 Feb 2016 07:15:00 +0100